A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process

Pulmonary fibrosis (PF) is chronic and irreversible damage to the lung characterized by fibroblast activation and matrix deposition. Although recently approved novel anti‐fibrotic agents can improve the lung function and survival of patients with PF, the overall outcomes remain poor. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi‐Hyoung, Jung, Seung‐Youn, Song, Kyung‐Hee, Park, Jeong‐In, Ahn, Jiyeon, Kim, Eun‐Ho, Park, Jong Kuk, Hwang, Sang‐Gu, Woo, Hee‐Jong, Song, Jie‐Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933341/
https://www.ncbi.nlm.nih.gov/pubmed/31692229
http://dx.doi.org/10.1111/jcmm.14793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933341/
https://www.ncbi.nlm.nih.gov/pubmed/31692229
http://dx.doi.org/10.1111/jcmm.14793

Ejemplares similares